PT1557462E - Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização - Google Patents

Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização Download PDF

Info

Publication number
PT1557462E
PT1557462E PT05009317T PT05009317T PT1557462E PT 1557462 E PT1557462 E PT 1557462E PT 05009317 T PT05009317 T PT 05009317T PT 05009317 T PT05009317 T PT 05009317T PT 1557462 E PT1557462 E PT 1557462E
Authority
PT
Portugal
Prior art keywords
transplant
acceptance
preparation
monocytic origin
induction cells
Prior art date
Application number
PT05009317T
Other languages
English (en)
Portuguese (pt)
Inventor
Bernd Karl Friedrich Kremer
Fred Faendrich
Maren Schulze
Original Assignee
Blasticon Biotech Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blasticon Biotech Forschung filed Critical Blasticon Biotech Forschung
Publication of PT1557462E publication Critical patent/PT1557462E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/001Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/17Monocytes; Macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22Immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/418Antigens related to induction of tolerance to non-self
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0645Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/22Colony stimulating factors (G-CSF, GM-CSF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/24Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT05009317T 2002-07-12 2003-07-11 Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização PT1557462E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10231655A DE10231655A1 (de) 2002-07-12 2002-07-12 Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
PT1557462E true PT1557462E (pt) 2008-06-18

Family

ID=30009939

Family Applications (2)

Application Number Title Priority Date Filing Date
PT05009317T PT1557462E (pt) 2002-07-12 2003-07-11 Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização
PT04701001T PT1644484E (pt) 2002-07-12 2004-01-09 Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT04701001T PT1644484E (pt) 2002-07-12 2004-01-09 Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas

Country Status (18)

Country Link
US (1) US20060286670A1 (enExample)
EP (2) EP1557462B1 (enExample)
JP (1) JP2005532803A (enExample)
CN (1) CN100523176C (enExample)
AT (2) ATE390480T1 (enExample)
AU (1) AU2003250939B2 (enExample)
BR (1) BR0312693A (enExample)
CA (1) CA2492383A1 (enExample)
DE (3) DE10231655A1 (enExample)
DK (2) DK1557462T3 (enExample)
ES (3) ES2304647T3 (enExample)
IL (3) IL166021A0 (enExample)
NO (1) NO20050719L (enExample)
PT (2) PT1557462E (enExample)
RU (1) RU2370535C2 (enExample)
SI (3) SI1492869T1 (enExample)
WO (1) WO2004007701A1 (enExample)
ZA (2) ZA200501054B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644484B1 (en) * 2003-07-11 2008-09-17 Blasticon Biotechnologische Forschung GmbH Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations
DE10362002B4 (de) 2003-06-23 2006-10-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Adulte pluripotente Stammzellen
EP1928479B1 (en) * 2005-08-24 2016-06-08 Yeda Research And Development Co., Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007116962A1 (ja) 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
CN101646459B (zh) 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
JP5544290B2 (ja) 2008-06-05 2014-07-09 独立行政法人国立がん研究センター 神経浸潤抑制剤
ES2615861T3 (es) * 2008-10-30 2017-06-08 Yeda Research And Development Company Ltd. Células T de memoria central anti-terceros, métodos de producción de las mismas y uso de las mismas en trasplante y tratamiento de enfermedades
JP5436905B2 (ja) * 2009-03-26 2014-03-05 テルモ株式会社 シート状細胞培養物の製造方法
JP5667357B2 (ja) * 2009-11-30 2015-02-12 テルモ株式会社 シート状細胞培養物の製造方法
CN101812428A (zh) * 2010-04-26 2010-08-25 西北农林科技大学 一种乳腺上皮细胞的组织块种植方法
HUE060454T2 (hu) 2010-05-28 2023-03-28 Chugai Pharmaceutical Co Ltd Daganatellenes T-sejt-választ fokozó szer
DE102011004335A1 (de) 2011-02-17 2012-08-23 Thomas Grammel Verfahren zur Herstellung eines Vakzins
RU2508924C1 (ru) * 2013-02-21 2014-03-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения отторжения почечного трансплантата
JP5727665B2 (ja) * 2014-12-11 2015-06-03 テルモ株式会社 シート状細胞培養物の製造方法
JP5893786B2 (ja) * 2015-04-02 2016-03-23 テルモ株式会社 シート状細胞培養物の製造方法
KR102769850B1 (ko) * 2015-07-03 2025-02-20 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 조절 t 세포를 수득하는 방법 및 이의 용도
JP6903866B2 (ja) * 2016-01-27 2021-07-14 国立大学法人 熊本大学 血液由来単球の増殖誘導方法
JP6140322B2 (ja) * 2016-02-24 2017-05-31 テルモ株式会社 シート状細胞培養物の製造方法
JP6490738B2 (ja) * 2017-04-28 2019-03-27 テルモ株式会社 シート状細胞培養物の製造方法
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
JP6657452B2 (ja) * 2019-02-27 2020-03-04 テルモ株式会社 シート状細胞培養物の製造方法
JP7002497B2 (ja) * 2019-06-20 2022-01-20 テルモ株式会社 シート状細胞培養物の製造方法
JP6872051B2 (ja) * 2020-02-05 2021-05-19 テルモ株式会社 シート状細胞培養物の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
US7410773B2 (en) * 1995-02-02 2008-08-12 Ghazi Jaswinder Dhoot Method of preparing an undifferentiated cell
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
ES2201177T3 (es) * 1995-03-08 2004-03-16 The Scripps Research Institute Sistema de presentacion de antigenos y activacion de celulas-t.
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
NL1017973C2 (nl) * 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
AU2002224851A1 (en) * 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

Also Published As

Publication number Publication date
DK1557462T3 (da) 2008-06-23
CA2492383A1 (en) 2004-01-22
IL166021A0 (en) 2006-01-15
AU2003250939B2 (en) 2008-05-22
RU2370535C2 (ru) 2009-10-20
SI1644484T1 (sl) 2009-02-28
ZA200501054B (en) 2005-08-30
HK1071586A1 (en) 2005-07-22
ATE390480T1 (de) 2008-04-15
DK1492869T3 (da) 2006-03-06
ES2252696T3 (es) 2006-05-16
IL172854A0 (en) 2006-06-11
ATE309331T1 (de) 2005-11-15
BR0312693A (pt) 2005-04-26
EP1557462A3 (en) 2006-02-01
CN1681918A (zh) 2005-10-12
US20060286670A1 (en) 2006-12-21
JP2005532803A (ja) 2005-11-04
DE60302231D1 (de) 2005-12-15
PT1644484E (pt) 2008-10-21
DE60302231T2 (de) 2006-07-20
RU2005103627A (ru) 2005-08-27
ES2310711T3 (es) 2009-01-16
SI1492869T1 (sl) 2006-04-30
WO2004007701A1 (en) 2004-01-22
EP1492869B1 (en) 2005-11-09
ES2304647T3 (es) 2008-10-16
DE60320009D1 (de) 2008-05-08
AU2003250939A1 (en) 2004-02-02
CN100523176C (zh) 2009-08-05
IL166021A (en) 2010-05-17
EP1557462A2 (en) 2005-07-27
DE10231655A1 (de) 2004-02-26
DE60320009T2 (de) 2009-05-20
EP1492869B9 (en) 2006-05-24
ZA200601074B (en) 2007-11-28
EP1557462B1 (en) 2008-03-26
NO20050719L (no) 2005-04-04
SI1557462T1 (sl) 2008-08-31
EP1492869A1 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
PT1557462E (pt) Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
BRPI0418286A (pt) proteìnas de fusão de il-7
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA200601670A1 (ru) Конъюгаты гидроксиалкилкрахмала и белка
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
EP1599228A4 (en) MODIFIED ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND THEIR USES
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
BR122018016045B8 (pt) proteína variante otimizada
CR8317A (es) Anticuerpos dirigidos a m-csf
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
EP1513397A4 (en) Transgenic mammals capable of producing human antibodies
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
BR0015872A (pt) Agentes antitrombóticos
ATE401344T1 (de) T-zellen-epitope in erythropoietin
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
EP1556499A4 (en) FOR CARCINOGENIC BACTERIA SPECIFIC MONOCLONAL ANTIBODIES
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
ATE535259T1 (de) Immunogener, monoklonaler antikörper
ATE295746T1 (de) Radioaktiv beschichtete stents
EA200501137A1 (ru) Способ и промежуточные соединения для получения оланзапина